NOVOZYMES A/S (NSIS-B.CO)

Every figure this model derived for NSIS-B.CO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 409,800,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 327,200,000 CashAndCashEquivalents 2026-04-01
current assets 2,045,700,000 CurrentAssets 2026-04-01
current liabilities 1,222,400,000 CurrentLiabilities 2026-04-01
equity 10,919,600,000 Equity 2026-04-01
interest expense 102,200,000 FinanceCosts 2025-12-31
ocf 1,221,500,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 4,157,600,000 Revenue 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NSIS-B.CO on one particular measure came for.

RatioValue
cash operating margin19.64
current ratio1.67
current ratio reported1.67
ev ebit37.99
ev owner earnings38.23
ev sales7.46
fcf margin19.52
interest cover7.99
net debt ebitda3.18
operating margin19.64
owner earnings margin19.52
revenue growth8.45
revenue growth per share8.45
roic4.77
rule of 4028.1
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about NSIS-B.CO's figures. Written by the derivation as it ran, not added afterwards.